Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.23 (¥4,355)+1.73%▲ (in JPY terms)
SoftBank|$22.25 (¥3,558)-4.82%▼ (in JPY terms)
MUFG|$21.78 (¥3,483)-0.43%▼ (in JPY terms)
Keyence|$468.00 (¥74,840)-0.25%▼ (in JPY terms)
Nintendo|$54.96 (¥8,789)+2.64%▲ (in JPY terms)
NTT|$1.05 (¥169)+0.60%▲ (in JPY terms)
Takeda|$43.07 (¥6,887)+0.91%▲ (in JPY terms)
Tokyo Electron|$59.18 (¥9,464)+1.72%▲ (in JPY terms)
Recruit|$111.12 (¥17,770)+6.31%▲ (in JPY terms)
ITOCHU|$15.10 (¥2,414)+0.06%▲ (in JPY terms)
Honda|$11.48 (¥1,836)+1.35%▲ (in JPY terms)
Shin-Etsu|$35.61 (¥5,694)-1.68%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.51%▲ (in JPY terms)
Fast Retailing|$514.40 (¥82,260)+2.58%▲ (in JPY terms)
Toyota|$17.68 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.23 (¥4,355)+1.73%▲ (in JPY terms)
SoftBank|$22.25 (¥3,558)-4.82%▼ (in JPY terms)
MUFG|$21.78 (¥3,483)-0.43%▼ (in JPY terms)
Keyence|$468.00 (¥74,840)-0.25%▼ (in JPY terms)
Nintendo|$54.96 (¥8,789)+2.64%▲ (in JPY terms)
NTT|$1.05 (¥169)+0.60%▲ (in JPY terms)
Takeda|$43.07 (¥6,887)+0.91%▲ (in JPY terms)
Tokyo Electron|$59.18 (¥9,464)+1.72%▲ (in JPY terms)
Recruit|$111.12 (¥17,770)+6.31%▲ (in JPY terms)
ITOCHU|$15.10 (¥2,414)+0.06%▲ (in JPY terms)
Honda|$11.48 (¥1,836)+1.35%▲ (in JPY terms)
Shin-Etsu|$35.61 (¥5,694)-1.68%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.51%▲ (in JPY terms)
Fast Retailing|$514.40 (¥82,260)+2.58%▲ (in JPY terms)

2026-08-20 Shiseido Company,Limited “A highly anticipated product that sold out immediately after its release on August 20, 2026*! Revital's eye pack, which provides under-eye bag care with a "pseudo-skin film that you apply," is finally back in stock!”

2026-08-20 Shiseido Company,Limited “A highly anticipated product that sold out immediately after its re … 続きを読む

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”

2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む